Myopia Control in 2026: Atropine, Lenslet Spectacles, Ortho-K and Red Light

Myopia Control in 2026: Atropine, Lenslet Spectacles, Ortho-K and Red Light

Last updated: October 2026

Key points in 60 seconds

  • Chase axial length: each dioptre of myopia prevented cuts myopic maculopathy risk by about 40%.
  • Measure axial length with optical biometry at baseline and every 6 months; refract with cycloplegia.
  • Options: outdoor time, low-dose atropine (0.01% more modest than hoped), defocus spectacles, multifocal soft lenses, ortho-k, red light.
  • Choose by age, progression rate, family preference and access; review every 6 months.

About half the world's population is projected to be myopic by 2050, and the proportion with high myopia is rising fastest. Myopia control is now a routine paediatric consultation. The evidence has moved quickly in the last three years, especially for atropine, which turned out more modest at 0.01% than many hoped.

Why we chase axial length, not just dioptres

  • The risks of myopic maculopathy, retinal detachment, glaucoma and cataract rise with axial length and degree of myopia.
  • Each dioptre of myopia prevented is estimated to cut the risk of myopic maculopathy by about 40%.
  • Measure axial length with optical biometry at baseline and every 6 months. Use cycloplegic refraction in children.

The options and the evidence

InterventionWhat the evidence showsPractical notes
Outdoor timeDelays onset; about 40–80 extra minutes a day is associated with lower incidence. A weaker effect once myopia has started.Free, safe, and advised for every child.
Low-dose atropineLAMP (Hong Kong): 0.05% was the most effective of 0.05%, 0.025% and 0.01%. LAMP2: 0.05% reduced new-onset myopia in pre-myopic children. CHAMP, PEDIG and MOSAIC: modest effect of 0.01% alone in more diverse populations.Many clinicians now prefer 0.025–0.05%. Effect depends on formulation. Taper rather than stop abruptly to limit rebound.
Lenslet (defocus) spectaclesDIMS (MiyoSmart) and HAL (Stellest) slow axial elongation by roughly 30–50%. Stellest received FDA authorisation in September 2025 for children aged 6–12 at the start of treatment. For every spectacle design side by side (DIMS, HAL, DOT, CARE, prismatic bifocals) and how to fit them, see myopia-control spectacle lenses.Good first option for younger children. Requires full-time wear and good centration. Long-term data now extend to 6–8 years.
Dual-focus soft contact lensesMiSight 1 day (FDA 2019): 0.73 D (59%) less progression and 0.32 mm (52%) less axial growth over 3 years, with benefit through 6 years and no rebound reported.Daily disposable. Suits motivated children from about age 8.
OrthokeratologyReduces axial elongation by about 0.2–0.3 mm over 2 years.Overnight wear carries a risk of microbial keratitis (including Acanthamoeba), so hygiene teaching is essential.
Repeated low-level red light (RLRL)Large short-term effects in Chinese trials, including combined with ortho-k.Safety is uncertain: retinal injury has been reported, some devices may exceed exposure limits, and rebound after stopping is a concern. Devices are not FDA-cleared. Do not combine with atropine (larger pupil).

Regulatory snapshot

  • United States: MiSight (2019) and Stellest (2025) are authorised. A low-dose atropine product (SYD-101) received a complete response letter from the FDA in October 2025, so atropine is still used off-label or compounded there.
  • India: low-dose atropine eye drops and myopia-control spectacle lenses are commercially available. Check the concentration and whether the formulation is preserved.

A practical approach

  1. Identify children at risk: early onset, both parents myopic, little outdoor time, or progression of 0.5 D a year or more.
  2. Record a baseline cycloplegic refraction and axial length, and compare against age-based growth charts.
  3. Start with outdoor time plus one optical treatment (lenslet spectacles or dual-focus contact lenses), or low-dose atropine, depending on age, family preference and cost.
  4. Review every 6 months. If axial growth remains fast, combine treatments (for example atropine with ortho-k or lenslet spectacles).
  5. Continue at least into the mid-teens, then taper and monitor for rebound.

Viva pearls

  • Peripheral myopic defocus is the shared principle behind DIMS, HAL, MiSight and ortho-k.
  • Know LAMP well: a concentration-dependent effect, with 0.05% the most effective and still well tolerated.
  • Atropine 0.05% enlarges the photopic pupil by about 1 mm and reduces accommodation by about 2 D, usually without affecting quality of life.
  • Ortho-k's main danger is microbial keratitis.

Related: atropine 0.01% eye drops in myopia, understanding myopia and amblyopia treatment updates.

Key sources

📘 Want more exam-ready material? See Most Commons in Ophthalmology on Kindle, or browse all my books.

How to cite this page

Patel D. Myopia Control in 2026: Atropine, Lenslet Spectacles, Ortho-K and Red Light. RPC Rounds (Sadbhaav Eye Clinic). Updated October 2026. Available at: https://www.sadbhaavclinic.com/myopia-control-2026.html. Accessed [date].

Written and medically reviewed by Dr. Dhaval Patel, MD (Ophthalmology, AIIMS New Delhi) · Editorial policy

Consultant, Cataract & Refractive Surgery — among a small number of AIIMS-trained ophthalmologists practicing in Gujarat. Read full credentials & experience or view his 28 publications on ResearchGate.

📚 Also the author of OKAT Decoded, FRCOphth Decoded and other high-yield ophthalmology exam-prep books used by residents and PG aspirants.

Looking for an eye specialist in Ahmedabad? Read about children's eye check-ups at Sadbhaav or book a consultation with Dr. Dhaval Patel.